XERS logo

Xeris Biopharma Holdings, Inc. (XERS) EBITDA

annual EBITDA:

-$13.99M+$9.74M(+41.04%)
December 31, 2024

Summary

  • As of today (September 16, 2025), XERS annual EBITDA is -$13.99 million, with the most recent change of +$9.74 million (+41.04%) on December 31, 2024.
  • During the last 3 years, XERS annual EBITDA has risen by +$99.67 million (+87.69%).
  • XERS annual EBITDA is now -6.90% below its all-time high of -$13.09 million, reached on December 31, 2016.

Performance

XERS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherXERSincome statement metrics

quarterly EBITDA:

$8.59M+$7.37M(+599.84%)
June 30, 2025

Summary

  • As of today (September 16, 2025), XERS quarterly EBITDA is $8.59 million, with the most recent change of +$7.37 million (+599.84%) on June 30, 2025.
  • Over the past year, XERS quarterly EBITDA has increased by +$11.73 million (+373.87%).
  • XERS quarterly EBITDA is now at all-time high.

Performance

XERS quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherXERSincome statement metrics

TTM EBITDA:

$7.39M+$11.73M(+270.38%)
June 30, 2025

Summary

  • As of today (September 16, 2025), XERS TTM EBITDA is $7.39 million, with the most recent change of +$11.73 million (+270.38%) on June 30, 2025.
  • Over the past year, XERS TTM EBITDA has increased by +$24.63 million (+142.89%).
  • XERS TTM EBITDA is now at all-time high.

Performance

XERS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherXERSincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

XERS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+41.0%+373.9%+142.9%
3 y3 years+87.7%+142.9%+106.2%
5 y5 years+88.1%+139.7%+106.7%

XERS EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+87.7%at high+142.9%at high+106.2%
5 y5-yearat high+88.1%at high+117.9%at high+105.9%
alltimeall time-6.9%+88.1%at high+117.9%at high+105.9%

XERS EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
$8.59M(+599.8%)
$7.39M(-270.4%)
Mar 2025
-
$1.23M(-78.5%)
-$4.34M(-69.0%)
Dec 2024
-$13.99M(-41.0%)
$5.72M(-170.2%)
-$13.99M(-39.3%)
Sep 2024
-
-$8.15M(+159.8%)
-$23.07M(+33.8%)
Jun 2024
-
-$3.14M(-62.8%)
-$17.24M(-30.3%)
Mar 2024
-
-$8.43M(+151.6%)
-$24.73M(+4.2%)
Dec 2023
-$23.73M(-65.8%)
-$3.35M(+44.2%)
-$23.73M(-7.9%)
Sep 2023
-
-$2.32M(-78.1%)
-$25.78M(-33.2%)
Jun 2023
-
-$10.63M(+42.9%)
-$38.57M(-19.6%)
Mar 2023
-
-$7.44M(+37.8%)
-$47.96M(-29.6%)
Dec 2022
-$69.31M(-39.0%)
-$5.40M(-64.3%)
-$68.09M(-38.5%)
Sep 2022
-
-$15.11M(-24.5%)
-$110.79M(-7.3%)
Jun 2022
-
-$20.01M(-27.4%)
-$119.57M(-4.3%)
Mar 2022
-
-$27.57M(-42.7%)
-$124.95M(+9.9%)
Dec 2021
-$113.67M
-$48.09M(+101.3%)
-$113.67M(+38.0%)
Sep 2021
-
-$23.89M(-6.0%)
-$82.39M(+14.8%)
Jun 2021
-
-$25.40M(+56.0%)
-$71.79M(+5.5%)
DateAnnualQuarterlyTTM
Mar 2021
-
-$16.28M(-3.2%)
-$68.04M(-14.0%)
Dec 2020
-$79.12M(-32.8%)
-$16.82M(+26.6%)
-$79.12M(-15.8%)
Sep 2020
-
-$13.29M(-38.6%)
-$93.93M(-14.3%)
Jun 2020
-
-$21.65M(-20.9%)
-$109.63M(-9.5%)
Mar 2020
-
-$27.36M(-13.5%)
-$121.08M(+2.8%)
Dec 2019
-$117.80M(+105.9%)
-$31.63M(+9.1%)
-$117.80M(+11.8%)
Sep 2019
-
-$28.99M(-12.4%)
-$105.36M(+16.6%)
Jun 2019
-
-$33.10M(+37.5%)
-$90.39M(+29.8%)
Mar 2019
-
-$24.08M(+25.5%)
-$69.64M(+21.7%)
Dec 2018
-$57.22M(+117.3%)
-$19.19M(+36.8%)
-$57.22M(+21.6%)
Sep 2018
-
-$14.03M(+13.6%)
-$47.07M(+16.2%)
Jun 2018
-
-$12.35M(+6.0%)
-$40.52M(+43.8%)
Mar 2018
-
-$11.65M(+28.9%)
-$28.17M(+33.3%)
Dec 2017
-$26.33M(+101.1%)
-$9.04M(+21.0%)
-$21.13M(+74.8%)
Sep 2017
-
-$7.47M(+62.1%)
-$12.09M(+162.1%)
Mar 2017
-
-$4.61M
-$4.61M
Dec 2016
-$13.09M
-
-

FAQ

  • What is Xeris Biopharma Holdings, Inc. annual EBITDA?
  • What is the all time high annual EBITDA for Xeris Biopharma Holdings, Inc.?
  • What is Xeris Biopharma Holdings, Inc. annual EBITDA year-on-year change?
  • What is Xeris Biopharma Holdings, Inc. quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Xeris Biopharma Holdings, Inc.?
  • What is Xeris Biopharma Holdings, Inc. quarterly EBITDA year-on-year change?
  • What is Xeris Biopharma Holdings, Inc. TTM EBITDA?
  • What is the all time high TTM EBITDA for Xeris Biopharma Holdings, Inc.?
  • What is Xeris Biopharma Holdings, Inc. TTM EBITDA year-on-year change?

What is Xeris Biopharma Holdings, Inc. annual EBITDA?

The current annual EBITDA of XERS is -$13.99M

What is the all time high annual EBITDA for Xeris Biopharma Holdings, Inc.?

Xeris Biopharma Holdings, Inc. all-time high annual EBITDA is -$13.09M

What is Xeris Biopharma Holdings, Inc. annual EBITDA year-on-year change?

Over the past year, XERS annual EBITDA has changed by +$9.74M (+41.04%)

What is Xeris Biopharma Holdings, Inc. quarterly EBITDA?

The current quarterly EBITDA of XERS is $8.59M

What is the all time high quarterly EBITDA for Xeris Biopharma Holdings, Inc.?

Xeris Biopharma Holdings, Inc. all-time high quarterly EBITDA is $8.59M

What is Xeris Biopharma Holdings, Inc. quarterly EBITDA year-on-year change?

Over the past year, XERS quarterly EBITDA has changed by +$11.73M (+373.87%)

What is Xeris Biopharma Holdings, Inc. TTM EBITDA?

The current TTM EBITDA of XERS is $7.39M

What is the all time high TTM EBITDA for Xeris Biopharma Holdings, Inc.?

Xeris Biopharma Holdings, Inc. all-time high TTM EBITDA is $7.39M

What is Xeris Biopharma Holdings, Inc. TTM EBITDA year-on-year change?

Over the past year, XERS TTM EBITDA has changed by +$24.63M (+142.89%)
On this page